X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This Phase 1 clinical trial with ADM03820 is part of a Department of Defense (DOD) award to manufacture and test anti-COVID-19 monoclonal antibodies.
Lead Product(s): ADM03820
Therapeutic Area: Infections and Infectious Diseases Product Name: ADM03820
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
The scope of this program includes the activities required to rapidly develop, manufacture, and obtain FDA licensure of a monoclonal antibody (mAb) cocktail (ADM03820) that was originally identified in a previous agreement with the DOD.
Lead Product(s): Anti-COVID-19 Monoclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Department of Defense for Advanced Development
Deal Size: $37.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 23, 2020
Details:
The vaccine candidate ATI-1701 is a novel attenuated version derived from the virulent SCHU S4 strain of tularemia. Ology Bio will manufacture the vaccine candidate and will perform a safety assessment using a rabbit model under collaboration with Appili Therapeutics.
Lead Product(s): ATI-1701
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Funding October 27, 2020
Details:
In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of critical vaccines and therapeutics for COVID-19. This work is in support of the Operation Warp Speed response to the ongoing pandemic.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S. Army Contracting Command
Deal Size: $106.3 million Upfront Cash: $53.1 million
Deal Type: Funding August 26, 2020
Details:
Ology has been awarded 3 contracts with a gross amount of over $16 million. The three biomanufacturing contracts are: produce a conjugated vaccine candidate for melloidosis, vaccine against glanders disease and manufacture a DNA vaccine against Venezuelan equine encephalitis.
Lead Product(s): DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $16.3 million Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2020
Details:
Ology Bioservices will use funds to advance anti-botulinum neurotoxin monoclonal antibodies study which is a randomized, double-blinded Phase 1 dose-escalation clinical trial of a cocktail of mAb against botulinum neurotoxin serotypes A and B.
Lead Product(s): Anti-botulinum neurotoxin monoclonal antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $42.6 million Upfront Cash: Undisclosed
Deal Type: Funding June 25, 2020
Details:
Funding will support Ology Bioservices establish their proprietary Veroplex ® cell platform to respond quickly to emerging viral diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $27.3 million Upfront Cash: Undisclosed
Deal Type: Funding April 22, 2020
Details:
Under this program, Ology Bioservices will work with Vanderbilt University Medical Center (VUMC) in Nashville, Tennessee to develop and manufacture the monoclonal antibody.
Lead Product(s): Monoclonal antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
